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ELEVATED LEVELS OF CD191 CD21- TRANSITIONAL B CELLS IN
CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) ASSOCIATED WITH
ELEVATED PLASMA BAFF LEVELS AND BAFF RECEPTOR EXPRESSION
Rehman, N.K., Dickinson, J., Baskar, S., Rader, C., Pavletic, S.Z.,
Gress, R.E., Hakim, F.T. National Cancer Institute, NIH, Bethesda,
MD.
B Cell Activating Factor (BAFF also termed BLyS) is a critical
factor in the survival, differentiation and function of B cells, but el-
evated plasma levels of BAFF have been associated with the devel-
opment of B-cell mediated autoimmunity, both in murine models
and in human disease. In mice BAFF administration-induced auto-
immunity has been linked to increased survival of the transitional B
cell population, resulting in a failure to eliminate auto-reactive B
cell populations by negative selection during B cell maturation. Mu-
rine studies had determined that only CD211T2/T3 transitional B
cells expressed the BAFF receptor and could be rescued by elevated
BAFF levels. In contrast, in man, we have determined that the more
immature circulating CD1911CD21– T1 transitional B cell sub-
population expresses the BAFF-R to the same degree as mature B
cells in both normal donors and patient populations. We therefore
concurrently investigated both plasma BAFF levels and
CD1911CD21– T1 transitional B cell frequencies in patients en-
tered into an ongoing NCI CGVHD natural history protocol. We
determined that plasma BAFF levels were elevated in many
CGVHD patients as compared with those in normal donors
(Mann Whitney p\ 0.0001). By multi-parameter flow cytometry
we further determined that the median percentage of
CD1911CD21– T1 transitional B cells in 71 CGVHD patients
was significantly higher than that in 40 normal adult donors
(Mann Whitney p \ 0.0001). Following transplantation, the B
cell population is reconstituted primarily by maturation of new B
cells from the marrow, hence an elevated frequency of transitional
B cells would be expected when mature B cell levels are low; transi-
tional CD1911CD21- B cell frequencies remain elevated over
normal, however, even in CGVHD patients with B cell levels
greater than 100 cells/microliter (p5 .003). Comparison of patients
in the upper and lower 50th percentile of plasma BAFF levels deter-
mined that the frequency of CD21– transitional B cells was signif-
icantly higher in those patients with higher BAFF levels (p 5
.001). Elevated frequencies of CD21– B cells in CGVHD patients
may therefore reflect elevated BAFF levels. Altered transitional B
cell survival may contribute to the later generation of pathologic
auto-reactivity by the survival of auto-antigen reactive immature
B cells.355
GCSF DECREASES CD41CD251CD127LO REGULATORY T CELL PRO-
LIFERATION INDEX IN STEM CELL DONORS
Khalili, J.S., Karandish, S., Bryan, S., Molldrem, J., McMannis, J.,
Komanduri, K.V. MD Anderson Cancer Center, Houston, TX.
Increasing the number of regulatory T cells (Tregs) in donor
grafts prevents acute graft-versus-host disease (aGVHD) in murine
models of hematopoetic stem cell transplant (HSCT). It has been
reported that filgrastim (G-CSF) mobilization increases the propor-
tion of donor graft CD41CD251T cells. This finding is bolstered
by evidence from murine models, and by in vitro systems demon-
strating an impaired response to mitogenic stimulation after in
vivo G-CSF. We can now more precisely identify human Tregs
by the markers CD127lo and Foxp3. To test the hypothesis that
G-CSF increases the proportion of Tregs in human HSC donors,
we phenotyped the donor graft T cell population of 15 individuals
who had both an unmobilized DLI collected by apheresis and a sep-
arate G-CSF mobilized graft. Our phenotyping included CD4,
CD25, CD127, Foxp3, CD8, markers of memory differentiation
(CD45RA, CD27) and the cell cycle protein Ki-67. G-CSF did
not alter the total proportion of CD41CD251CD127lo Tregs in
the CD4 compartment, % Tregs baseline (mean 5 4.82, SD 5
1.08, 95% CI 5 4.30–5.42), % Tregs after G-CSF (mean 5 5.08,
SD 5 1.22, 95% CI 5 4.40–5.75). When we examined the cycling
fraction of various lymphoid subsets, we first observed that at base-line, Tregs had a much higher proliferative index (%Ki-671) than
other blood subpopulations. Furthermore, proliferation within
the Treg compartment decreased significantly following G-CSF
treatment (Table 1). We also found a G-CSF treatment-related de-
crease in proliferative index in the (non-Treg) CD41 compartment
and a trend toward increased proliferation within the B/NK com-
partment. To exclude direct effects of G-CSF on T cells we tested
for the presence of CD114 (G-CSFR) on T cells by flow cytometry,
and found none. Furthermore G-CSF treatment of PBMC (50 ng/
mL for 5 d) did not influence the proliferative index of conventional
CD41, CD81, or Tregs after in vitro T cell stimulation, suggest-
ing that the mechanism by which G-CSF reduces Treg proliferative
index in HSC donors is indirect. Since depletion of the host lym-
phoid population via conditioning presumably facilitates the expan-
sion of transferred donor graft lymphocytes, it will be important to
test if variations in the proliferative index of transferrred Tregs or
other lymphoid subsets results in an altered ‘‘proliferative momen-
tum’’ in HSCT recipients, which might influence the rate of Treg
recovery and, potentially, aGVHD rates after HSCT.Cell Population Ki-67 Proliferation Index
Non-TTreg (CD41
CD251 CD127 lo)CD41
T cellCD81
T cellcell Lymphocytes
(B cell & NK)Baseline 8.2 ± 2.5
(6.8, 9.6)2.0 ± 0.7
(1.6, 2.5)2.3 ± 1.0
(1.7, 2.8)5.1 ± 1.6
(4.2, 6.0)GCSF 6.2 ± 2.6
(4.7, 7.7)1.5 ± 0.7
(1.1, 1.9)2.9 ± 2.5
(1.5, 4.3)11.2 ± 12.1
(4.5, 17.9)t-test
(paired)\0.0001 0.01 0.36 .057Mean 6 1 SD (95% CI).356
PHASE-II STUDY OF INFLIXIMAB FOR THE PROPHYLAXIS OF ACUTE
GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT)
Hamadani, M.1, Phillips, G.2, Elder, P.1, Jansak, B.1, Blum, W.1,
Penza, S.1, Lin, T.S.1, Farag, S.S.3, Devine, S.M.1. 1Arthur G. James
Cancer Hospital, Ohio State University, Columbus, OH; 2Arthur G.
James Cancer Hospital, Ohio State University, Columbus, OH; 3 Indiana
University School of Medicine, Indianapolis, IN.
Introduction: Infliximab is a chimeric monoclonal antibody that
binds with high affinity to the soluble and transmembrane forms of
tumor necrosis factor-a, and inhibits their binding with the cellular
receptors. A number of retrospective studies have shown activity of
this drug in the treatment of steroid refractory acute (a) GVHD. We
conducted a prospective phase-II trial of infliximab for prophylaxis
of aGVHD following AHSCT. Methods: Selection criteria in-
cluded age .20 yrs, sibling (Sib) or unrelated donor (URD) avail-
ability and myeloablative (MA) AHSCT for hematologic
malignancies (except CML in 1st chronic phase and aplastic ane-
mia). Prophylaxis for aGVHD consisted of infliximab (10 mg/kg/
dose) given 1 day prior to starting MA conditioning and subse-
quently on days 0,17,114,128 and142, cyclosporine and meth-
otrexate (15 mg/m2 day 1 & 10 mg/m2 days 3,6,11). Results:
Nineteen patients (pts) were prospectively enrolled. There were
13 male and 6 female pts with a median age of 53 yrs (range 27–
64 yrs). Diagnoses included AML/MDS (n 5 11), NHL (n 5 4)
and ALL (n 5 4). Donors included matched Sib (n 5 14), matched
URD (n 5 4) and mismatched URD (n 5 1). 15 pts received MA
conditioning with busulphan/cyclophosphamide, while 4 received
TBI. All pts received peripheral blood stem cells. Prospectively en-
rolled pts getting infliximab (IG) were compared with a matched
control group (CG) (n 5 30). Pts in CG were matched for age, di-
agnosis, donor type, HLA typing, GVHD prophylaxis, condition-
ing regimen and stem cell source with IG. Median number of
CD341 cells in IG and CG was 4.95 and 5.22  106 cells/kg of
Poster Session II 131recipient respectively. Cumulative incidence of grade II-IV
aGVHD in IG and CG was 25% and 35% respectively (p .
0.05). No difference was seen in days to onset of aGVHD between
the two groups. Patient age, sex, donor type and conditioning reg-
imen had no effect on the probability of response to infliximab.
Rates of chronic GVHD in IG and CG were 84% and 61% respec-
tively (p5 0.22). Pts in IG had significantly more fungal infections
(n5 5) compared to CG (n5 1) (p5 0.02). Kaplan-Meier estimates
of 3 yr overall survival for IG and CG were 31% and 38% respec-
tively (p 5 0.42). Estimates of 3 yr progression free survival are
59% and 56% in similar order (p 5 0.68). Conclusion: In conclu-
sion, infliximab does not reduce incidence of grade II-IV aGVHD
compared to historic controls. It causes a significant increase in fun-
gal infections and may increase the likelihood of chronic GVHD.357
GRAFT-VERSUS-HOST DISEASE: A MINOR-MISMATCHEDMOUSE MODEL
WITH GRADUAL PROGRESSION FROM THE ACUTE INTO THE CHRONIC
PHASE
Mueller, A.M.S.1,2, Allen, J.A.1, Miklos, D.1, Shizuru, J.A.1. 1Stanford
School of Medicine, Stanford, CA; 2University Medical Center, Freiburg
i.Br., Germany.
Chronic graft-versus-host disease (cGVHD) is the most frequent
long-term complication after allogeneic hematopoietic cell trans-
plantation (HCT). While acute GVHD (aGVHD) is largely donor
T cell (TC) induced, the pathophysiology of cGVHD remains un-
clear. Amongst the issues to be clarified are the identification of the
TC subsets that drive the pathophysiology, the delineation of anti-
gen targets and the role of B cells (BC). Most experimental models
study acute GVHD, whereas models for the chronic phase are
scarce. C57BL/6 (B6)/BALB. B (H2Db) is an established mi-
nor-mismatched mouse model for aGVHD. Here, we assessed
whether mice also develop chronic long-term symptoms. Lethally
irradiated recipients were given FACS purified hematopoietic
stem cells (HSC: cKit1Thy1.1loLin-Sca11). For induction of
GVHD titrated doses of splenocytes (SP; 5  105–1  107) or pu-
rified CD4 or CD8 TC were co-transferred. Mice were followed
over an extended time (1 y) for clinical signs, weight loss, histology,
chimerism, and IgG synthesis (donor/host). Recipients of pure
HSC remained healthy, steadily increasing in weight (107% of
baseline (BL); d100). Mice given SP developed aGVHD with mor-
bidity and mortality correlating to the SP dose. Survivors of the
acute phase stabilized by d50–70, with only subtle signs for months,
and weight remained below BL (d100: 93%/83% for 106/107 SP, re-
spectively). Ultimately, they developed a full-blown picture of
cGVHD, with erythrosquamous skin lesions, alopecia, cirrhotic
liver changes, and conjunctivitis at 1 y post-HCT. The most re-
markable histological changes were inflammatory periportal liver
infiltrates, which gradually progressed to fibrosis and complete dis-
ruption of a regular cell pattern. Intestines were primarily affected
in the acute phase, whereas skin changes (subcutaneous atrophy, in-
filtration of hair follicles) manifested late. CD4, but not CD8 TC
induced the full picture of aGVHD. Recipients of HSC remained
mixed chimeras, addition of SP promptly converted recipients to
full donor chimeras. Delays in BC reconstitution correlated with
the degree of aGVHD. Despite this, high levels of donor IgG syn-
thesis were observed. In conclusion, B6/ BALB. B is a valuable
model to study cGVHD with convincing histological signs evolving
from acute changes. Mouse studies delineating the GVHD-induc-
ing TC subsets will improve our understanding of the pathophysi-
ology of GVHD, and will be an essential piece paving the way of
graft engineering.358
THE PTPN22 1858C/T POLYMORPHISM IS ASSOCIATED WITH THE DE-
VELOPMENT OF GRADE 3 TO 4 ACUTE GRAFT-VERSUS-HOST DISEASE
AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOL-
LOWING NONMYELOABLATIVE CONDITIONING
Kornblit, B.1,2, Masmas, T.1, Petersen, S.L.1, Madsen, H.O.2,
Garred, P.2, Vindelov, L.1. 1Rigshospitalet, University of Copenhagen,Copenhagen, Denmark; 2Rigshospitalet, University of Copenhagen, Co-
penhagen, Denmark.
Graft-versus-host disease (GVHD) is a cause of considerable
morbidity and mortality after allogeneic hematopoietic cell trans-
plantation (HCT) following nonmyeloablative conditioning. Ge-
netic polymorphisms in various genes, associated with the
immune system have been implicated in the development of
GVHD. The PTPN22 gene encodes LYP, which is involved in sup-
pression of T-cell receptor signalling. The 1858 C/T polymor-
phism in PTPN22, renders T-cells hyperresponsive, and the 1858
T allele has been implicated in conferring increased susceptibility
to various autoimmune diseases. As in autoimmunity, T-cell activa-
tion plays a key role in the development of GVHD. To asses the in-
fluence of the PTPN22 1858 C/T polymorphism on development
of GVHD after allogeneic HCT following nonmyeloablative con-
ditioning, 100 consecutive patient-donor pairs receiving allogeneic
HCT with related (n5 66) or unrelated (n5 34) donors for hema-
tological malignancies (HD 5 13, MM 5 14, CLL 5 12, NHL 5
17, MDS 5 18, AML 5 24, CML 5 2), between March 2000 and
December 2005 at Rigshospitalet, Denmark, were genotyped.
The cumulative incidence of grade 2–4 acute GVHD, grade 3–4
acute GVHD and extensive chronic GVHD was 67%, 24%, and
49%, with no difference between patients carrying the C/C or C/
T and T/T genotype or donors carrying the C/C or C/T and T/
T genotype. To assess a possible gene-dosage effect, the number
of T-alleles in each recipient-donor pair was cumulated, and the cu-
mulative incidence of grade 3–4 acute GVHD increased from 20%
in recipient-donor pairs carrying no or one T-allele to 50% in recip-
ient-donor pairs carrying two or more T alleles (p 5 0.04), while
there was no difference in grade 2–4 acute and extensive chronic
GVHD between groups. In the competing risk regression analysis,
the recipient-donor pair genotype with 2 or more T-alleles was an
independent risk factor (hazard ratio 3.0; 95% CI 1.2–7.5) for devel-
opment of grade 3–4 acute GVHD, even after adjusting for baseline
variables known to affect GVHD rates. Furthermore, patients from
recipient-donor pairs carrying two or more T-alleles were hospital-
ized for more days (p 5 0.01) due to GVHD (median 5 15 days;
range 0–63 d), than patients from recipient-donor pairs with no
or one T-allele (median 5 0 days; range 0–104 d). Collectively,
our data suggest, that the PTPN22 1858 C/T polymorphism,
when present in both recipient and donor, is a risk factor for devel-
opment of grade 3–4 acute GVHD after nonmyeloablative condi-
tioning allogeneic HCT.359
IMMUNE ACTIVATION WITH INTERLEUKIN-2 AND GRANULOCYTE-
MACROPHAGE COLONY STIMULATING FACTOR FOR TREATMENT OF RE-
LAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Bachier, C.R., Shaughnessy, P., Smith, B., Salinas, R., LeMaistre, C.F.
Texas Transplant Institute, San Antonio, TX.
Donor lymphocyte infusion (DLI) is use for relapse after alloge-
neic stem cell transplant (ASCT). Immune activation with cytokines
maybe an alternative to DLI. We studied the use of Granulocyte-
Macrophage Colony Stimulating Factor (GM-CSF) and Interleu-
kin-2 (IL-2) for immune activation at the time of relapse after
ASCT in patients (pts) with hematologic malignancies. Pts. received
subcutaneous GM-CSF at 500 mcg/day on days 1–14 and IL-2 at 1
 106 units/m2/day on days 8–14. Pts. were off immunosuppressive
therapy and had no prior history of graft versus host disease
(GVHD) at the start of treatment. Twelve pts. received IL-2/
GM-CSF for treatment of relapse AML (7), ALL (2), CML (1),
MDS (2). Median age was 55 (range 8–66). Stem cell sources in-
cluded: peripheral blood 5 9, bone marrow 5 2, umbilical cord
blood (UCB) 5 1. Donor sources were: match-related sibling 5 4
and match-unrelated donor5 8 (UCB5 1). Nine pts. had resistant
relapse or primary resistant disease at time of ASCT. Median time
from transplant to relapse was 4 months (range 5 1–14). Two pts.
had failed DLI and 5 pts. had received reinduction chemotherapy
prior to IL-2/GM-CSF. Eight pts. responded to IL-2/GM-CSF
(CR5 7, PR5 1). Two pts. remain disease free at 18 and 26 months
post IL-2/GM-CSF. Six pts. developed GVHD and of these 4
were responders. Two pts. had GM-CSF discontinued due to in-
crease in peripheral blood blasts. No other toxicities related to
